Literature DB >> 19196961

CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity.

Han Seok Ko1, Rachel Bailey, Wanli W Smith, Zhaohui Liu, Joo-Ho Shin, Yun-Il Lee, Yong-Jie Zhang, Haibing Jiang, Christopher A Ross, Darren J Moore, Cam Patterson, Leonard Petrucelli, Ted M Dawson, Valina L Dawson.   

Abstract

Mutation in leucine-rich repeat kinase-2 (LRRK2) is the most common cause of late-onset Parkinson's disease (PD). Although most cases of PD are sporadic, some are inherited, including those caused by LRRK2 mutations. Because these mutations may be associated with a toxic gain of function, controlling the expression of LRRK2 may decrease its cytotoxicity. Here we show that the carboxyl terminus of HSP70-interacting protein (CHIP) binds, ubiquitinates, and promotes the ubiquitin proteasomal degradation of LRRK2. Overexpression of CHIP protects against and knockdown of CHIP exacerbates toxicity mediated by mutant LRRK2. Moreover, HSP90 forms a complex with LRRK2, and inhibition of HSP90 chaperone activity by 17AAG leads to proteasomal degradation of LRRK2, resulting in increased cell viability. Thus, increasing CHIP E3 ligase activity and blocking HSP90 chaperone activity can prevent the deleterious effects of LRRK2. These findings point to potential treatment options for LRRK2-associated PD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19196961      PMCID: PMC2650345          DOI: 10.1073/pnas.0810123106

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  41 in total

1.  Clinical and positron emission tomography of Parkinson's disease caused by LRRK2.

Authors:  Dena G Hernandez; Coro Paisán-Ruíz; Aideen McInerney-Leo; Shushant Jain; Andreas Meyer-Lindenberg; E Whitney Evans; Karen F Berman; Janel Johnson; Georg Auburger; Alejandro A Schäffer; Grisel J Lopez; Robert L Nussbaum; Andrew B Singleton
Journal:  Ann Neurol       Date:  2005-03       Impact factor: 10.422

2.  An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family.

Authors:  Manabu Funayama; Kazuko Hasegawa; Etsuro Ohta; Noriko Kawashima; Masaru Komiyama; Hisayuki Kowa; Shoji Tsuji; Fumiya Obata
Journal:  Ann Neurol       Date:  2005-06       Impact factor: 10.422

3.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease.

Authors:  R Krüger; W Kuhn; T Müller; D Woitalla; M Graeber; S Kösel; H Przuntek; J T Epplen; L Schöls; O Riess
Journal:  Nat Genet       Date:  1998-02       Impact factor: 38.330

4.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism.

Authors:  T Kitada; S Asakawa; N Hattori; H Matsumine; Y Yamamura; S Minoshima; M Yokochi; Y Mizuno; N Shimizu
Journal:  Nature       Date:  1998-04-09       Impact factor: 49.962

5.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease.

Authors:  M H Polymeropoulos; C Lavedan; E Leroy; S E Ide; A Dehejia; A Dutra; B Pike; H Root; J Rubenstein; R Boyer; E S Stenroos; S Chandrasekharappa; A Athanassiadou; T Papapetropoulos; W G Johnson; A M Lazzarini; R C Duvoisin; G Di Iorio; L I Golbe; R L Nussbaum
Journal:  Science       Date:  1997-06-27       Impact factor: 47.728

6.  Identification of CHIP, a novel tetratricopeptide repeat-containing protein that interacts with heat shock proteins and negatively regulates chaperone functions.

Authors:  C A Ballinger; P Connell; Y Wu; Z Hu; L J Thompson; L Y Yin; C Patterson
Journal:  Mol Cell Biol       Date:  1999-06       Impact factor: 4.272

7.  Kinase activity of mutant LRRK2 mediates neuronal toxicity.

Authors:  Wanli W Smith; Zhong Pei; Haibing Jiang; Valina L Dawson; Ted M Dawson; Christopher A Ross
Journal:  Nat Neurosci       Date:  2006-09-17       Impact factor: 24.884

8.  A common LRRK2 mutation in idiopathic Parkinson's disease.

Authors:  William P Gilks; Patrick M Abou-Sleiman; Sonia Gandhi; Shushant Jain; Andrew Singleton; Andrew J Lees; Karen Shaw; Kailash P Bhatia; Vincenzo Bonifati; Niall P Quinn; John Lynch; Daniel G Healy; Janice L Holton; Tamas Revesz; Nicholas W Wood
Journal:  Lancet       Date:  2005 Jan 29-Feb 4       Impact factor: 79.321

9.  Kinase activity is required for the toxic effects of mutant LRRK2/dardarin.

Authors:  Elisa Greggio; Shushant Jain; Ann Kingsbury; Rina Bandopadhyay; Patrick Lewis; Alice Kaganovich; Marcel P van der Brug; Alexandra Beilina; Jeff Blackinton; Kelly Jean Thomas; Rili Ahmad; David W Miller; Sashi Kesavapany; Andrew Singleton; Andrew Lees; Robert J Harvey; Kirsten Harvey; Mark R Cookson
Journal:  Neurobiol Dis       Date:  2006-06-05       Impact factor: 5.996

10.  Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease.

Authors:  Coro Paisán-Ruíz; Shushant Jain; E Whitney Evans; William P Gilks; Javier Simón; Marcel van der Brug; Adolfo López de Munain; Silvia Aparicio; Angel Martínez Gil; Naheed Khan; Janel Johnson; Javier Ruiz Martinez; David Nicholl; Itxaso Martí Carrera; Amets Saénz Pena; Rohan de Silva; Andrew Lees; José Félix Martí-Massó; Jordi Pérez-Tur; Nick W Wood; Andrew B Singleton
Journal:  Neuron       Date:  2004-11-18       Impact factor: 17.173

View more
  99 in total

Review 1.  Rodent models and contemporary molecular techniques: notable feats yet incomplete explanations of Parkinson's disease pathogenesis.

Authors:  Sharawan Yadav; Anubhuti Dixit; Sonal Agrawal; Ashish Singh; Garima Srivastava; Anand Kumar Singh; Pramod Kumar Srivastava; Om Prakash; Mahendra Pratap Singh
Journal:  Mol Neurobiol       Date:  2012-06-27       Impact factor: 5.590

2.  The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK/ERK pathway.

Authors:  José M Bravo-San Pedro; Mireia Niso-Santano; Rubén Gómez-Sánchez; Elisa Pizarro-Estrella; Ana Aiastui-Pujana; Ana Gorostidi; Vicente Climent; Rakel López de Maturana; Rosario Sanchez-Pernaute; Adolfo López de Munain; José M Fuentes; Rosa A González-Polo
Journal:  Cell Mol Life Sci       Date:  2012-07-08       Impact factor: 9.261

3.  Regulation of autophagic flux by CHIP.

Authors:  Dongkai Guo; Zheng Ying; Hongfeng Wang; Dong Chen; Feng Gao; Haigang Ren; Guanghui Wang
Journal:  Neurosci Bull       Date:  2015-07-28       Impact factor: 5.203

Review 4.  Molecular chaperones in Parkinson's disease--present and future.

Authors:  Darius Ebrahimi-Fakhari; Lara Wahlster; Pamela J McLean
Journal:  J Parkinsons Dis       Date:  2011       Impact factor: 5.568

5.  A QUICK screen for Lrrk2 interaction partners--leucine-rich repeat kinase 2 is involved in actin cytoskeleton dynamics.

Authors:  Andrea Meixner; Karsten Boldt; Marleen Van Troys; Manor Askenazi; Christian J Gloeckner; Matthias Bauer; Jarrod A Marto; Christophe Ampe; Norbert Kinkl; Marius Ueffing
Journal:  Mol Cell Proteomics       Date:  2010-09-27       Impact factor: 5.911

Review 6.  E3 ubiquitin ligases in protein quality control mechanism.

Authors:  Deepak Chhangani; Ajay Prakash Joshi; Amit Mishra
Journal:  Mol Neurobiol       Date:  2012-05-19       Impact factor: 5.590

7.  The G2385R variant of leucine-rich repeat kinase 2 associated with Parkinson's disease is a partial loss-of-function mutation.

Authors:  Iakov N Rudenko; Alice Kaganovich; David N Hauser; Aleksandra Beylina; Ruth Chia; Jinhui Ding; Dragan Maric; Howard Jaffe; Mark R Cookson
Journal:  Biochem J       Date:  2012-08-15       Impact factor: 3.857

Review 8.  Role of LRRK2 kinase dysfunction in Parkinson disease.

Authors:  Azad Kumar; Mark R Cookson
Journal:  Expert Rev Mol Med       Date:  2011-06-13       Impact factor: 5.600

Review 9.  Ubiquitin/proteasome pathway impairment in neurodegeneration: therapeutic implications.

Authors:  Qian Huang; Maria E Figueiredo-Pereira
Journal:  Apoptosis       Date:  2010-11       Impact factor: 4.677

10.  E3 ligase STUB1/CHIP regulates NAD(P)H:quinone oxidoreductase 1 (NQO1) accumulation in aged brain, a process impaired in certain Alzheimer disease patients.

Authors:  Peter Tsvetkov; Yaarit Adamovich; Evan Elliott; Yosef Shaul
Journal:  J Biol Chem       Date:  2011-01-10       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.